Long-term outcomes in patients with persistent EBV-DNA positivity after primary Epstein-Barr virus infection and clinical implications of rituximab therapy
Patients with primary EBV infection of B cells are unlikely to progress to malignant disease transformation despite persistent EBV-DNA positivity. Nonetheless, there is a potential risk of chronic lymphoproliferation. Rituximab treatment is a safe and efficient method for eliminating EBV-infected B cells and achieving rapid clearance of EBV-DNA.
Authors
- Miao Zheng (ORCID: https://orcid.org/0000-0003-3962-7209)
- Ziying Hong (ORCID: https://orcid.org/0000-0003-4160-9739)
- Yaxian Ma (ORCID: https://orcid.org/0000-0002-5634-9821)
- Qing Yin (ORCID: https://orcid.org/0009-0009-7317-7564)
- Liting Chen (ORCID: https://orcid.org/0000-0002-7786-1226)
- Min Liu (ORCID: https://orcid.org/0000-0001-5183-1187)
- Jia Gu
Institutions
- Tongji Hospital (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- International Immunopharmacology
- Published
- 2025-04-21
- DOI
- https://doi.org/10.1016/j.intimp.2025.114695
- Primary Topic
- Viral-associated cancers and disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00